The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes
Abstract Diabetes is common in patients with chronic obstructive pulmonary disease. Sodium-glucose co-transporter-2 inhibitors are effective in treating type 2 diabetes and provide benefits for conditions like cardiovascular and kidney diseases. We use data from multiple institutions and countries t...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-60582-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849768743656226816 |
|---|---|
| author | Jheng-Yan Wu Khai-Chi Hu Mei-Yuan Liu Yu-Jou Wu Wan-Hsuan Hsu Ya-Wen Tsai Ting-Hui Liu Po-Yu Huang Min-Hsiang Chuang Tsung Yu Kuang-Ming Liao Chih-Cheng Lai |
| author_facet | Jheng-Yan Wu Khai-Chi Hu Mei-Yuan Liu Yu-Jou Wu Wan-Hsuan Hsu Ya-Wen Tsai Ting-Hui Liu Po-Yu Huang Min-Hsiang Chuang Tsung Yu Kuang-Ming Liao Chih-Cheng Lai |
| author_sort | Jheng-Yan Wu |
| collection | DOAJ |
| description | Abstract Diabetes is common in patients with chronic obstructive pulmonary disease. Sodium-glucose co-transporter-2 inhibitors are effective in treating type 2 diabetes and provide benefits for conditions like cardiovascular and kidney diseases. We use data from multiple institutions and countries to evaluate their role in patients with chronic obstructive pulmonary disease and diabetes. This study includes chronic obstructive pulmonary disease patients with diabetes who are newly prescribed sodium-glucose co-transporter-2 inhibitors or dipeptidyl peptidase-4 inhibitors between January 1, 2013, and August 25, 2024. The primary outcome is all-cause mortality. The results show that the sodium-glucose co-transporter-2 inhibitors group has a lower risk of all-cause mortality compared to the dipeptidyl peptidase-4 inhibitors group (hazard ratio, 0.757; 95% confidence interval, 0.716-0.801). It also shows significantly lower risks of all-cause hospitalization (hazard ratio, 0.864; 95% confidence interval, 0.845-0.884), exacerbation (hazard ratio, 0.924; 95% confidence interval, 0.888-0.962), pneumonia, upper respiratory infections, bronchitis, and major cardiovascular events. |
| format | Article |
| id | doaj-art-920295cf4a174df29f0c6f991658ef4f |
| institution | DOAJ |
| issn | 2041-1723 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj-art-920295cf4a174df29f0c6f991658ef4f2025-08-20T03:03:41ZengNature PortfolioNature Communications2041-17232025-07-011611810.1038/s41467-025-60582-yThe clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetesJheng-Yan Wu0Khai-Chi Hu1Mei-Yuan Liu2Yu-Jou Wu3Wan-Hsuan Hsu4Ya-Wen Tsai5Ting-Hui Liu6Po-Yu Huang7Min-Hsiang Chuang8Tsung Yu9Kuang-Ming Liao10Chih-Cheng Lai11Department of Nutrition, Chi Mei Medical CenterDivision of Chest medicine, Department of Internal Medicine, Chi Mei Medical CenterDepartment of Nutrition, Chi Mei Medical CenterDepartment of Internal Medicine, Chi Mei Medical CenterDepartment of Internal Medicine, Chi Mei Medical CenterCenter of Integrative Medicine, Chi Mei Medical CenterDepartment of Psychiatry, Chi Mei Medical CenterDepartment of Internal Medicine, Chi Mei Medical CenterDivision of Nephrology, Department of Internal Medicine, Chi Mei Medical CenterDepartment of Public Health, College of Medicine, National Cheng Kung UniversityDepartment of Internal Medicine, Chi Mei Medical Center, ChialiDepartment of Intensive Care Medicine, Chi Mei Medical CenterAbstract Diabetes is common in patients with chronic obstructive pulmonary disease. Sodium-glucose co-transporter-2 inhibitors are effective in treating type 2 diabetes and provide benefits for conditions like cardiovascular and kidney diseases. We use data from multiple institutions and countries to evaluate their role in patients with chronic obstructive pulmonary disease and diabetes. This study includes chronic obstructive pulmonary disease patients with diabetes who are newly prescribed sodium-glucose co-transporter-2 inhibitors or dipeptidyl peptidase-4 inhibitors between January 1, 2013, and August 25, 2024. The primary outcome is all-cause mortality. The results show that the sodium-glucose co-transporter-2 inhibitors group has a lower risk of all-cause mortality compared to the dipeptidyl peptidase-4 inhibitors group (hazard ratio, 0.757; 95% confidence interval, 0.716-0.801). It also shows significantly lower risks of all-cause hospitalization (hazard ratio, 0.864; 95% confidence interval, 0.845-0.884), exacerbation (hazard ratio, 0.924; 95% confidence interval, 0.888-0.962), pneumonia, upper respiratory infections, bronchitis, and major cardiovascular events.https://doi.org/10.1038/s41467-025-60582-y |
| spellingShingle | Jheng-Yan Wu Khai-Chi Hu Mei-Yuan Liu Yu-Jou Wu Wan-Hsuan Hsu Ya-Wen Tsai Ting-Hui Liu Po-Yu Huang Min-Hsiang Chuang Tsung Yu Kuang-Ming Liao Chih-Cheng Lai The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes Nature Communications |
| title | The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes |
| title_full | The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes |
| title_fullStr | The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes |
| title_full_unstemmed | The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes |
| title_short | The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes |
| title_sort | clinical effectiveness of sodium glucose co transporter 2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes |
| url | https://doi.org/10.1038/s41467-025-60582-y |
| work_keys_str_mv | AT jhengyanwu theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT khaichihu theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT meiyuanliu theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT yujouwu theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT wanhsuanhsu theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT yawentsai theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT tinghuiliu theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT poyuhuang theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT minhsiangchuang theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT tsungyu theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT kuangmingliao theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT chihchenglai theclinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT jhengyanwu clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT khaichihu clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT meiyuanliu clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT yujouwu clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT wanhsuanhsu clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT yawentsai clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT tinghuiliu clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT poyuhuang clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT minhsiangchuang clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT tsungyu clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT kuangmingliao clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes AT chihchenglai clinicaleffectivenessofsodiumglucosecotransporter2inhibitorsonprognosisofpatientswithchronicobstructivepulmonarydiseaseanddiabetes |